Cargando…

Enhanced anti‐tumor effects of the PD‐1 blockade combined with a highly absorptive form of curcumin targeting STAT3

PD‐1/PD‐L1 immune checkpoint inhibitors are promising cancer immunotherapies however responses are still limited and the development of more effective combination immunotherapy is needed. We previously reported that STAT3 activation in cancer cells and immune cells was involved in immune‐resistant m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayakawa, Taeko, Yaguchi, Tomonori, Kawakami, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734012/ https://www.ncbi.nlm.nih.gov/pubmed/33006786 http://dx.doi.org/10.1111/cas.14675

Ejemplares similares

Enhanced anti-tumor effects of the PD-1/PD-L1 blockade by combining a highly absorptive form of NF-kB/STAT3 inhibitor curcumin
por: Hayakawa, Taeko, et al.
Publicado: (2014)

Inhibition of vascular adhesion protein‐1 enhances the anti‐tumor effects of immune checkpoint inhibitors
por: Kinoshita, Tomonari, et al.
Publicado: (2021)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023)

Development of anti-GPC-1 (glypican-1)-CAR-T cells for adoptive T cell immunotherapies for squamous cell carcinoma
por: Yaguchi, Tomonori, et al.
Publicado: (2015)

PD-L1 blockade enhances anti-tumor efficacy of NK cells
por: Oyer, Jeremiah L., et al.
Publicado: (2018)

GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab
por: Kato, Daiki, et al.
Publicado: (2020)

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
por: Irving, Bryan A, et al.
Publicado: (2013)

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
por: Rubio-Pérez, Laura, et al.
Publicado: (2023)

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
por: Chen, Shaomeng, et al.
Publicado: (2021)

Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma
por: Lucarini, Valeria, et al.
Publicado: (2022)

Comparative absorption of curcumin formulations
por: Jäger, Ralf, et al.
Publicado: (2014)

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)

Combinatorial sympathetic and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockades inhibit the murine melanoma growth by targeting infiltrating T cells
por: Wang, Bin, et al.
Publicado: (2021)

Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer
por: Wang, Yue, et al.
Publicado: (2018)

Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling
por: Yu, Chao, et al.
Publicado: (2023)

Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody
por: Katoh, Yuki, et al.
Publicado: (2022)

Preclinical to clinical translation of anti-PD-1 blockade
por: Hirsch, Heather, et al.
Publicado: (2015)

MHC class I/II deficient NOG mice are useful for analysis of human T/B cell responses for human tumor immunology research
por: Yaguchi, Tomonori, et al.
Publicado: (2013)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Optimum fractionation of radiation to combine PD‐1 blockade
por: Teng, Feifei, et al.
Publicado: (2023)

Immunosuppression through HNF-1β signaling in human ovarian clear cell cancer
por: Nishio, Hiroshi, et al.
Publicado: (2013)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
por: Koller, Paul, et al.
Publicado: (2023)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors
por: Benguigui, Madeleine, et al.
Publicado: (2022)

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
por: Lewis, Katherine E., et al.
Publicado: (2017)

Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma
por: Shao, Liwei, et al.
Publicado: (2022)

Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells
por: Zhu, Mei, et al.
Publicado: (2021)

Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy
por: Guan, Xiudong, et al.
Publicado: (2018)

TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment
por: Park, Miso, et al.
Publicado: (2023)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
por: Spahn, Jessica, et al.
Publicado: (2015)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade
por: Velu, Vijayakumar, et al.
Publicado: (2008)

PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2022)

CHD7 promotes proliferation of neural stem cells mediated by MIF
por: Ohta, Shigeki, et al.
Publicado: (2016)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
por: Li, Yuan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cioheb9f391mosj5nmt2oijm90